A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

MLA

Lavinia Tan, et al. “A Phase II Trial of Alternating Osimertinib and Gefitinib Therapy in Advanced EGFR-T790M Positive Non-Small Cell Lung Cancer: OSCILLATE.” Nature Communications, vol. 15, no. 1, Feb. 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1038/s41467-024-46008-1.

APA

Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, Kenneth O’Byrne, Sagun Parakh, Victoria Bray, Kevin Jasas, Sonia Yip, Stephen Q. Wong, Sarah Ftouni, Jerick Guinto, Sushma Chandrashekar, Stephen Clarke, Nick Pavlakis, Martin R. Stockler, … Benjamin J. Solomon. (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1), 1–13. https://doi.org/10.1038/s41467-024-46008-1

Chicago

Lavinia Tan, Chris Brown, Antony Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni Newnham, et al. 2024. “A Phase II Trial of Alternating Osimertinib and Gefitinib Therapy in Advanced EGFR-T790M Positive Non-Small Cell Lung Cancer: OSCILLATE.” Nature Communications 15 (1): 1–13. doi:10.1038/s41467-024-46008-1.